Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections |
| |
Authors: | Peppard William J Schuenke Christopher D |
| |
Affiliation: | Froedtert Hospital, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA. wpeppard@fmlh.edu |
| |
Abstract: | Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the potential treatment of methicillin-resistant Staphylococcus aureus infections, including complicated skin and skin structure infections and hospital-acquired pneumonia. Phase III cSSSI clinical trials have been completed and an NDA filing process is ongoing. A phase II clinical trial for hospital-acquired pneumonia is ongoing. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|